Dissemin is shutting down on January 1st, 2025

Published in

Nature Research, Nature, 7696(555), p. 321-327, 2018

DOI: 10.1038/nature25480

Links

Tools

Export citation

Search in Google Scholar

The landscape of genomic alterations across childhood cancers

Journal article published in 2018 by Christof von Kalle, Marie-Laure Yaspo, Thorsten Zenz, Barbara C. Worst, Marc Weniger, Seq Project]Lichter P. [Icgc Mmml, Seq Project]Weber U. [Icgc Mmml, Seq Project]Eils R. [Icgc Mmml, Seq Project]Korshunov A. [Icgc Mmml, Seq Project]Witt O. [Icgc Mmml, Seq Project]Pfister S. [Icgc Mmml, Seq Project]Reifenberger G. [Icgc Mmml, Seq Project]Felsberg J. [Icgc Mmml, Seq Project]von Kalle C. [Icgc Mmml, Seq Project]Schmidt M. [Icgc Mmml and other authors.
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

Abstract Pan-cancer analyses that examine commonalities and differences among various cancer types have emerged as a powerful way to obtain novel insights into cancer biology. Here we present a comprehensive analysis of genetic alterations in a pan-cancer cohort including 961 tumours from children, adolescents, and young adults, comprising 24 distinct molecular types of cancer. Using a standardized workflow, we identified marked differences in terms of mutation frequency and significantly mutated genes in comparison to previously analysed adult cancers. Genetic alterations in 149 putative cancer driver genes separate the tumours into two classes: small mutation and structural/copy-number variant (correlating with germline variants). Structural variants, hyperdiploidy, and chromothripsis are linked to TP53 mutation status and mutational signatures. Our data suggest that 7–8% of the children in this cohort carry an unambiguous predisposing germline variant and that nearly 50% of paediatric neoplasms harbour a potentially druggable event, which is highly relevant for the design of future clinical trials.